Pharma News

Novo’s FDA warning is a reminder that compliance pressure grows alongside commercial success.

India’s API exports beating imports is a meaningful sign of deeper manufacturing confidence.

The founders’ planned exit marks a generational shift for BioNTech and the mRNA story it helped define.

Ingredient inflation is turning medicine pricing into a supply-chain problem, not just a pharma one.

Lilly’s $3 billion China plan signals long-term confidence in local demand and manufacturing depth.

The recent West Asia crisis is doing more than dominating geopolitical headlines. It is exposing how vulnerable pharmaceutical trade can become when shipping corridors turn unstable.

South Africa’s push to manufacture Gilead’s long-acting HIV prevention drug lenacapavir locally is one of the clearest signs yet that the future of access is being framed not only around licensing, but around geography.

China’s approval of Pfizer’s GLP-1 therapy Xianweiying for long-term weight management is more than another product authorization. It is a sign that the country’s obesity and metabolic-health market is entering a far more competitive phase.

The most striking part of the latest semaglutide story is not scientific at all. It is economic. A recent study highlighted by ETPharma argues that semaglutide, the active ingredient behind blockbuster products such as Ozempic and Wegovy, could potentiall

At first glance, the seizure of insulin stocks worth more than Rs 20 lakh in Delhi looks like a routine enforcement action. Yet the case carries a broader warning for India’s pharmaceutical distribution chain.

Key 2026 pharmaceutical regulatory updates across UAE, Saudi Arabia, GCC, Egypt and global agencies, with practical compliance insights for pharma companies.

• UAE
• MENA region
• Drugs
• Regulation
• pharmaceutical policy

Merck plans to cut ~150 jobs at its US Gardasil plant as global HPV vaccine sales drop, reflecting shifting demand and production strategy.

In a bold strategic pivot that could redefine its future, Glenmark Pharmaceuticals is betting big on oncology—with a $1 billion milestone-laden deal for a cutting-edge Chinese cancer drug poised to hit its licensed markets by FY28.

From the U.S. FDA’s progressive approach to drug labeling to European market pressures confronting legacy drugmakers, the landscape is shifting beneath industry feet.

In a candid address to investors and industry stakeholders, Novo Nordisk’s CEO Mike Doustdar has signaled that the Danish pharmaceutical giant expects notable headwinds within its international operations throughout 2026.

U.S. Food and Drug Administration (FDA) took an action that offered palpable relief to the global weight-loss drug market: it instructed pharmaceutical companies to remove warnings about “suicidal ideation and suicidal behavior” from the labels of certain

With the patent expiry of semaglutide—the active ingredient behind blockbuster drugs like Ozempic and Wegovy—in India, select regulated markets, and emerging economies, a massive revenue opportunity exceeding ₹50,000 crore (approximately $6 billion) has o

Novo Nordisk has officially launched an oral version of its blockbuster drug Wegovy in the United States, offering a needle-free alternative for millions who dread daily injections.

When iFlytek, Alipay, and Baidu each secured government healthcare AI contracts worth over RMB 100 million within a single month, the entire industry seemed to be wheeled out of the ICU and into a VIP recovery suite—breathing easier, pulse stabilizing, ey

Sanofi’s decision to acquire Dynavax Technologies for USD 2.2 billion in an all-cash transaction is far more than a portfolio expansion — it is a signal that the vaccine market is entering a new competitive era shaped by adult immunization, geopolitical s